Taipei, Taiwan

Chuan-Ming Lai

This inventor holds 1 USPTO granted patent. Top assignee: Development Center for Biotechnology. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chuan-Ming Lai: Innovator in Controlled Release Dosage Forms

Introduction

Chuan-Ming Lai is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled release dosage forms. His innovative work has led to the filing of a patent that showcases his expertise and dedication to improving drug delivery systems.

Latest Patents

Chuan-Ming Lai holds a patent for a controlled release tacrine dosage form. This invention aims to enhance the therapeutic efficacy of tacrine, a drug used in the treatment of Alzheimer's disease. The patent reflects his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Lai is currently associated with the Development Center for Biotechnology, where he applies his knowledge and skills to further research and development in biotechnology. His work at this institution has positioned him as a key player in the field, contributing to various innovative projects.

Collaborations

Chuan-Ming Lai has collaborated with esteemed colleagues, including Pao-Nien Chen and Shu-Jian Liu. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, ultimately leading to groundbreaking advancements in their respective fields.

Conclusion

Chuan-Ming Lai's contributions to the field of pharmaceuticals through his patent and work at the Development Center for Biotechnology highlight his role as an influential inventor. His dedication to innovation continues to pave the way for advancements in drug delivery systems.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…